Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with Acute Myeloid Leukemia (AML) who are in their first full remission but have features that make relapse more likely, such as a previous blood disorder, leukemia caused by prior cancer treatment, leukemia that spread outside the bone marrow, needing more than one round of treatment to reach remission, certain genetic risk factors, or being unable to tolerate standard follow-up chemotherapy.
• People with AML who are in their second or later remission.
• People with AML whose leukemia cells are not visible under a microscope but where abnormal genetic or cell markers are still detected.
• People diagnosed with Acute Lymphoblastic Leukemia (ALL) who are in their first full remission with high-risk features, such as certain high-risk chromosome changes, remaining detectable leukemia cells after initial treatment, or being unable to tolerate standard follow-up or maintenance chemotherapy.
• People with ALL who are in their second or later remission, including those with less than 5% leukemia cells but persistent abnormal genetic or cell markers.
• People with other types of acute leukemia of mixed or unclear cell type, where fewer than 5% leukemia cells are present or where only abnormal markers (not visible leukemia cells) remain.
• People with Myelodysplastic Syndromes (MDS) or related bone marrow disorders (other than myelofibrosis) that are classified as intermediate-2 or high risk, have life-threatening low blood cell counts, carry genetic changes that raise the risk of progressing to AML, or are MDS/MPD overlap conditions without myelofibrosis — provided that fewer than 10% leukemia cells are present in the bone marrow at the time of transplant assessment.
• People with aggressive Non-Hodgkin Lymphoma (NHL) — such as diffuse large B-cell, mantle cell, or T-cell types — who are in full remission as confirmed by PET/CT scan.
• People with less aggressive (indolent) B-cell NHL — such as follicular, small cell, or marginal zone types — who have had a second or later relapse and are in partial or full remission on PET/CT scan.
• People with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) who are in full remission (confirm with trial site).
• People who have a Karnofsky performance score of 80% or higher, meaning they are able to carry out normal activity with only minor symptoms.
• People whose kidneys are working well enough, with a calculated clearance rate above 70 ml/min.
• People with bilirubin (a liver marker) below 1.5 mg/dL, unless the elevation is due to a harmless inherited condition or red blood cell breakdown.
• People with liver enzyme levels (ALT) below three times the normal upper limit.
• People with lung function test results (FVC, FEV1, and DLCO) above 60% of what is expected for their age and size.
• People with a heart pumping function (ejection fraction) above 50%.
• People with a blood protein (albumin) level above 3.0.
• People with a transplant health score (HCT-CI) of 5 or below, which measures overall health suitability for transplant.
• People for whom suitable cord blood units can be found that meet specific matching, cell count, and storage requirements as assessed by the trial team.

Who may not be able to join:

• People diagnosed with myelofibrosis or any cancer involving moderate to severe scarring of the bone marrow.
• People who have active leukemia involvement in the fluid or tissue around the brain and spinal cord at the time of screening.
• People who have received checkpoint inhibitor (immunotherapy) treatments within the past 12 months.
• People who have previously had two stem cell transplants of any type.
• People who had one autologous (using their own cells) stem cell transplant within the past 12 months.
• People who have previously had an allogeneic (using another person's cells) stem cell transplant.
• People who have had prior radiation therapy to an area of the body that would make it unsafe to deliver the radiation used in this trial, as determined by a radiation specialist.
• People with an active infection that is not under control at the time of transplant.
• People with HIV infection.
• People who test positive for HTLV-1 (a virus that affects the immune system).
• People whose organ function or overall health status does not meet the required standards.
• People who are pregnant or breastfeeding.
• People, or their legal guardians, who are unable to give informed consent or are unable to follow the full treatment plan, supportive care requirements, long-term follow-up, or research testing involved in the trial.

Important: Always verify eligibility with the trial site directly before applying.